-
公开(公告)号:US20120022020A1
公开(公告)日:2012-01-26
申请号:US13193977
申请日:2011-07-29
IPC分类号: A61K31/715
CPC分类号: A61K9/2027 , A61K9/2072
摘要: A pharmaceutical composition containing a sulfated glycosaminoglycan drug and a polycationic polymer or copolymer wherein the proportion of ammonium groups in the pharmaceutical composition is between 0.01-2.0 μmol ammonium groups/mg pharmaceutical composition, the proportion of glycosaminoglycan in the pharmaceutical form is between 15% to 50% w/w, and the pharmaceutical composition possesses a moisture content of 10% wt or less. A pharmaceutical dosage form containing the pharmaceutical composition, and their use for the treatment of diseases or disorders therapeutically responsive to the glycosaminoglycan.
摘要翻译: 含有硫酸化糖胺聚糖药物和聚阳离子聚合物或共聚物的药物组合物,其中药物组合物中铵基团的比例为0.01-2.0μmol/ mg药物组合物,药物形式中糖胺聚糖的比例为15%至 50%w / w,药物组合物的含水量为10重量%以下。 含有药物组合物的药物剂型及其用于治疗对糖胺聚糖治疗反应的疾病或病症的用途。
-
公开(公告)号:US08802156B2
公开(公告)日:2014-08-12
申请号:US13193977
申请日:2011-07-29
CPC分类号: A61K9/2027 , A61K9/2072
摘要: A pharmaceutical composition containing a sulfated glycosaminoglycan drug and a polycationic polymer or copolymer wherein the proportion of ammonium groups in the pharmaceutical composition is between 0.01-2.0 μmol ammonium groups/mg pharmaceutical composition, the proportion of glycosaminoglycan in the pharmaceutical form is between 15% to 50% w/w, and the pharmaceutical composition possesses a moisture content of 10% wt or less. A pharmaceutical dosage form containing the pharmaceutical composition, and their use for the treatment of diseases or disorders therapeutically responsive to the glycosaminoglycan.
摘要翻译: 含有硫酸化糖胺聚糖药物和聚阳离子聚合物或共聚物的药物组合物,其中药物组合物中铵基团的比例为0.01-2.0μmol/ mg药物组合物,药物形式中糖胺聚糖的比例为15%至 50%w / w,药物组合物的含水量为10重量%以下。 含有药物组合物的药物剂型及其用于治疗对糖胺聚糖治疗反应的疾病或病症的用途。
-
公开(公告)号:US20100316722A1
公开(公告)日:2010-12-16
申请号:US12779556
申请日:2010-05-13
IPC分类号: A61K9/14 , A61K31/727 , A61K31/702 , A61P7/02
CPC分类号: A61K9/1635 , A61K9/1647 , A61K9/5138 , A61K9/5153
摘要: Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa.
摘要翻译: 含有至少一种活性化合物和聚合物基质的药物形式,其中所述聚合物基质包含至少一种具有阳离子性质的聚合物和至少一种可生物降解聚合物,其制备方法,包含所述药物形式的药物制剂及其用途。 药物形式提供活性化合物在粘膜上的增强的吸收。
-
公开(公告)号:US08361509B2
公开(公告)日:2013-01-29
申请号:US13355763
申请日:2012-01-23
IPC分类号: A61K9/14
CPC分类号: A61K9/1635 , A61K9/1647 , A61K9/5138 , A61K9/5153
摘要: Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa.
摘要翻译: 含有至少一种活性化合物和聚合物基质的药物形式,其中所述聚合物基质包含至少一种具有阳离子性质的聚合物和至少一种可生物降解聚合物,其制备方法,包含所述药物形式的药物制剂及其用途。 药物形式提供活性化合物在粘膜上的增强的吸收。
-
公开(公告)号:US08257744B2
公开(公告)日:2012-09-04
申请号:US12779556
申请日:2010-05-13
CPC分类号: A61K9/1635 , A61K9/1647 , A61K9/5138 , A61K9/5153
摘要: Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa.
摘要翻译: 含有至少一种活性化合物和聚合物基质的药物形式,其中所述聚合物基质包含至少一种具有阳离子性质的聚合物和至少一种可生物降解聚合物,其制备方法,包含所述药物形式的药物制剂及其用途。 药物形式提供活性化合物在粘膜上的增强的吸收。
-
公开(公告)号:US20120189698A1
公开(公告)日:2012-07-26
申请号:US13355763
申请日:2012-01-23
CPC分类号: A61K9/1635 , A61K9/1647 , A61K9/5138 , A61K9/5153
摘要: Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa.
摘要翻译: 含有至少一种活性化合物和聚合物基质的药物形式,其中所述聚合物基质包含至少一种具有阳离子性质的聚合物和至少一种可生物降解聚合物,其制备方法,包含所述药物形式的药物制剂及其用途。 药物形式提供活性化合物在粘膜上的增强的吸收。
-
-
-
-
-